A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
NCT06774131Phase 3Recruiting
- Lead sponsor
- UroGen Pharma Ltd. (Industry)
- Enrollment
- 70 (estimated)
- Start date
- 6 Aug 2025
- Primary completion
- Mar 2027 (estimated)
- Study completion
- 1 Mar 2028
- Last update posted
- 3 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- UGN-104 Drug
Conditions and primary outcome
- Upper Urinary Tract Urothelial Carcinoma
- Urothelial Carcinoma
Primary outcome
Complete response rate (CRR) (3 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06774131.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06774131 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.